NEW YORK (GenomeWeb News) — Lipomics today said it will provide its lipid metabolite services to Isis Pharmaceuticals.
 
Under the terms of the agreement, Lipomics will support Isis in its pre-clinical and clinical trials of lipid compounds that may be used to treat metabolic diseases.
 
Lipomics said it will hold exclusive rights to develop diagnostics that result from the research, while Isis will retain rights to therapeutics.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.

The New York Times reports that United Nations delegates have been discussing how to govern the genetic resources of the deep sea.

Researchers have transplanted edited cells into mice that appear to combat cocaine addiction, New Scientist reports.

In PNAS this week: analysis of proteolytic enzymes secreted by circulating tumor cells, phylogenetic study of Fv1 evolution, and more.